A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study

• Male or female as assigned at birth ≥ 18 years of age at the time of screening

• Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosisthrough physical examination by the investigator

• Non-segmental vitiligo, as assessed at screening, as

• ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5

• ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition tohands and feet) and T-VASI score = 3 to 60

Exclusion Criteria:

• Individuals unable or unwilling to follow the study procedures and/or to completethe study-related questionnaires

• Presence of segmental or mixed vitiligo, or other skin comorbidities that mayinterfere with study assessments (e.g., hypopigmented mycosis fungoides, geneticdiseases with pigmentary aberrations [such as piebaldism, Waardenburg, etc.],chemical- or druginduced leukoderma, etc.)

• Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors

• Individual who previously attempted or completed depigmentation therapy for NSV

• Use of prohibited medication & treatments. Other protocol-definedinclusion/exclusion criteria may apply